Literature DB >> 8099620

Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid.

G Nowak1, R Trullas, R T Layer, P Skolnick, I A Paul.   

Abstract

Chronic (14 daily injections) treatment of mice with the prototypic tricyclic antidepressant imipramine significantly alters ligand binding to the N-methyl-D-aspartate (NMDA) receptor complex. These effects were compared to a chronic regimen of 1-aminocyclopropanecarboxylic acid, a high-affinity partial agonist at strychnine-insensitive glycine receptors which mimics the effects of imipramine in preclinical models predictive of antidepressant action. Changes in the NMDA receptor complex after chronic, but not acute treatment with imipramine were manifested as: 1) a reduction in the potency of glycine to inhibit [3H]5,7-dichlorokynurenic acid binding to strychnine-insensitive glycine receptors; 2) a decrease in the proportion of high-affinity glycine sites inhibiting [3H]CGP 39653 binding to NMDA receptors; and 3) a decrease in basal [3H]MK-801 binding (under nonequilibrium conditions) to sites within NMDA receptor-coupled cation channels which was reversible by the addition of glutamate. These effects were observed in cerebral cortex, but not in hippocampus, striatum or basal forebrain. Chronic treatment with 1-aminocyclopropanecarboxylic acid resulted in changes which paralleled those of imipramine on ligand binding to the NMDA receptor complex, but the reduction in basal [3H]MK-801 binding did not achieve statistical significance. These findings indicate that adaptive changes in the NMDA receptor complex could be a feature common to chronic treatment with structurally unrelated antidepressants.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099620

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 3.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

4.  Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study.

Authors:  P A Boyer; P Skolnick; L H Fossom
Journal:  J Mol Neurosci       Date:  1998-06       Impact factor: 3.444

5.  Chronic dosing with 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, modulates NMDA inhibition of muscarinic-coupled PI hydrolysis in rat cortical slices.

Authors:  K M Boje; S S Lakhman
Journal:  Neurochem Res       Date:  1998-09       Impact factor: 3.996

6.  D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.

Authors:  JoAnn Difede; Judith Cukor; Katarzyna Wyka; Megan Olden; Hunter Hoffman; Francis S Lee; Margaret Altemus
Journal:  Neuropsychopharmacology       Date:  2013-11-12       Impact factor: 7.853

Review 7.  Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.

Authors:  Jing Wang; Liang Jing; Juan-Carlos Toledo-Salas; Lin Xu
Journal:  Neurosci Bull       Date:  2014-12-06       Impact factor: 5.203

Review 8.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

Review 10.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.